(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.37%) $78.40
(0.47%) $2.15
(0.41%) $2 318.00
(1.57%) $27.11
(-0.27%) $962.70
(0.02%) $0.929
(-0.08%) $10.87
(0.00%) $0.797
(0.00%) $91.45
2 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 8.17%
3.37% $ 3.07
@ $4.90
Wydano: 14 vas. 2024 @ 22:50
Zwrot: -37.28%
Poprzedni sygnał: vas. 14 - 20:56
Poprzedni sygnał:
Zwrot: 2.30 %
Live Chart Being Loaded With Signals
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer...
Stats | |
---|---|
Dzisiejszy wolumen | 1.34M |
Średni wolumen | 2.26M |
Kapitalizacja rynkowa | 524.12M |
EPS | $0 ( 2024-05-01 ) |
Następna data zysków | ( $-0.390 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.470 |
ATR14 | $0.00600 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-22 | Moore Timothy L. | Sell | 17 360 | Common Stock |
2024-03-14 | Chang David D | Sell | 53 393 | Common Stock |
2024-01-30 | Parker Geoffrey M. | Buy | 190 | Common Stock |
2024-01-25 | Moore Timothy L. | Buy | 341 515 | Stock Option (Right to buy) |
2024-01-25 | Moore Timothy L. | Buy | 96 600 | Common Stock |
INSIDER POWER |
---|
93.40 |
Last 94 transactions |
Buy: 32 219 312 | Sell: 32 079 170 |
Wolumen Korelacja
Allogene Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
HEPA | 0.96 |
ULCC | 0.955 |
JBLU | 0.953 |
RIDE | 0.953 |
NGM | 0.953 |
TCMD | 0.952 |
IMBI | 0.952 |
FNCH | 0.951 |
VCNX | 0.95 |
ALLR | 0.95 |
10 Najbardziej negatywne korelacje | |
---|---|
SKYA | -0.962 |
LEGA | -0.957 |
BRIV | -0.955 |
ADAL | -0.953 |
TBSAU | -0.951 |
TBSA | -0.95 |
CRZN | -0.949 |
LDHA | -0.949 |
FTPA | -0.949 |
AGGR | -0.949 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Allogene Therapeutics Inc Korelacja - Waluta/Towar
Allogene Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $95 000.00 |
Zysk brutto: | $-242.82M (-255 598.95 %) |
EPS: | $-2.09 |
FY | 2023 |
Przychody: | $95 000.00 |
Zysk brutto: | $-242.82M (-255 598.95 %) |
EPS: | $-2.09 |
FY | 2022 |
Przychody: | $243 000 |
Zysk brutto: | $-16.49M (-6 783.95 %) |
EPS: | $-2.30 |
FY | 2021 |
Przychody: | $38.49M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.14 |
Financial Reports:
No articles found.
Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej